Please assess the completion status of the following clinical trial:

Trial Title: International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documentation of CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:~  * Sweat chloride greater than or equal to 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT);~ * Two well-characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; or~ * Abnormal nasal potential difference.~* PA present in expectorated sputum or throat swab culture at Screening.~* FEV1 between (and including) 25% and 75% predicted at Screening.~* Negative pregnancy test at Screening.~* Ability to perform reproducible pulmonary function tests.~* Arterial oxygen saturation (SaO2) greater than or equal to 90% on room air at Screening.~* Ability to provide written informed consent.~Exclusion Criteria:~* Administration of antipseudomonal antibiotics by inhalation, IV, or oral routes (including azithromycin) within 14 days of Screening.~* Current use of oral corticosteroids in doses exceeding the equivalent of 10 mg prednisone/day or 20 mg prednisone every other day.~* History of sputum or throat swab culture yielding Burkholderia cepacia in the previous 2 years.~* History of daily continuous oxygen supplementation or requirement for more than 2 liters/minute at night.~* Administration of any investigational drug or use of any investigational device within 28 days of Screening and within 6 half-lives of the investigational drug (whichever was longer).~* Known local or systemic hypersensitivity to monobactam antibiotics.~* Inability to tolerate short-acting bronchodilator use at least three times daily.~* Changes in protocol-permitted antimicrobial, bronchodilator, anti-inflammatory, or corticosteroid medications within 7 days prior to Screening or between Screening and the next visit.~* Changes in physiotherapy technique or schedule within 7 days prior to Screening or between Screening and the next visit.~* History of lung transplantation.~* A chest x-ray indicating abnormal findings at Screening or within the previous 90 days.~* Abnormal renal or hepatic function at Screening.~* Any serious or active medical or psychiatric illness which, in the opinion of the investigator, would have interfered with participant treatment, assessment, or compliance with the protocol.~* Use of aerosolized hypertonic saline (except for sputum induction) during the 14 days preceding Visit 1.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo three times a day (TID) (Type: PLACEBO_COMPARATOR): None
- AZLI 75 mg three times a day (TID) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete